Press Release
Ability Pharmaceuticals launches a new updated website with a fresh design
February 20, 2017
Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced the launch of its new web site (www.abilitypharma.com)
The site includes extensive and updated information to provide a detailed overview of the company, its products under development and ongoing projects. It will also help visitors stay informed with the latest news of the company, their publications and the attending events, specifically featured in the “Media Center” section.
Visitors can now benefit from a contemporary design and a richer online content that is easier to navigate. Moreover, the new website has been created with the user experience firmly in mind, and it has been designed using the latest technology so the site is compatible with today's browsers and mobile devices without the need for Adobe Flash to view it.
“I can’t tell you how excited we are about this new website. AbilityPharma has really grown and matured in the last year and we needed a website that truly reflected who we’ve became,” said Carles Domènech, Chief Executive Officer and co-founder of AbilityPharma.
About Ability Pharmaceuticals
AbilityPharma is a biopharmaceutical company focused on creating the future of oncology by developing innovative therapies that address unmet medical needs. Established in 2009 and with one product, ABTL0812, an oral autophagy targeted therapy in phase 2 clinical trials in patients with endometrial cancer and in squamous NSCLC, is positioning itself as one of the fast growers in the Catalan and Spanish biotech sector.
In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with the NASDAQ US company SciClone Pharmaceuticals, Inc. to develop and market the product in Greater China.
Ability Pharmaceuticals has headquarters in Cerdanyola del Vallès (Barcelona, Catalonia, Spain) at Parc Tecnològic del Vallès and Parc de Recerca UAB. Current shareholders include the biotech venture firms Inveready and SODENA, its founders and private investors, and has the financial support from ACCIO (Government of Catalonia), CDTI, ENISA and MINECO (Government of Spain).
The site includes extensive and updated information to provide a detailed overview of the company, its products under development and ongoing projects. It will also help visitors stay informed with the latest news of the company, their publications and the attending events, specifically featured in the “Media Center” section.
Visitors can now benefit from a contemporary design and a richer online content that is easier to navigate. Moreover, the new website has been created with the user experience firmly in mind, and it has been designed using the latest technology so the site is compatible with today's browsers and mobile devices without the need for Adobe Flash to view it.
“I can’t tell you how excited we are about this new website. AbilityPharma has really grown and matured in the last year and we needed a website that truly reflected who we’ve became,” said Carles Domènech, Chief Executive Officer and co-founder of AbilityPharma.
About Ability Pharmaceuticals
AbilityPharma is a biopharmaceutical company focused on creating the future of oncology by developing innovative therapies that address unmet medical needs. Established in 2009 and with one product, ABTL0812, an oral autophagy targeted therapy in phase 2 clinical trials in patients with endometrial cancer and in squamous NSCLC, is positioning itself as one of the fast growers in the Catalan and Spanish biotech sector.
In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with the NASDAQ US company SciClone Pharmaceuticals, Inc. to develop and market the product in Greater China.
Ability Pharmaceuticals has headquarters in Cerdanyola del Vallès (Barcelona, Catalonia, Spain) at Parc Tecnològic del Vallès and Parc de Recerca UAB. Current shareholders include the biotech venture firms Inveready and SODENA, its founders and private investors, and has the financial support from ACCIO (Government of Catalonia), CDTI, ENISA and MINECO (Government of Spain).
LATEST NEWS
14.12.2022
Press Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022
Press Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022
Press Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
07.10.2022
Press Release
AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info
07.09.2022
Press Release
Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info
29.06.2022
Press Release
AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info
13.06.2022
Press Release
AbilityPharma Will Attend the ESMO Gynaecological Cancers Congress 2022 in Valencia + info
10.06.2022
Press Release
AbilityPharma Will Attend BIO 2022 in San Diego as Part of the European Innovation Council (EIC) Delegation with a Booth in the European Pavilion + info
